SYDNEY, June 06, 2025 (GLOBE NEWSWIRE) — Leading online FX and CFD broker Axi attended the Finance Magnates Africa Summit (FMAS:25), held on May 29-30, 2025, at the Cape Town International Convention Centre in Cape Town, South Africa. Event attendees were introduced to Axi Select, Axi’s capital allocation program launched in 2023. The program, designed […]
SYDNEY, June 06, 2025 (GLOBE NEWSWIRE) — Leading online FX and CFD broker Axi attended the Finance Magnates Africa Summit (FMAS:25), held on May 29-30, 2025, at the Cape Town International Convention Centre in Cape Town, South Africa. Event attendees were introduced to Axi Select, Axi’s capital allocation program launched in 2023. The program, designed […]
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ibotta, Inc. (NYSE: IBTA): (1) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Ibotta’s April 18, 2024 initial public offering (the “IPO”); or […]
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ibotta, Inc. (NYSE: IBTA): (1) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Ibotta’s April 18, 2024 initial public offering (the “IPO”); or […]
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO” or the […]
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO” or the […]